Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Novo Nordisk (NOV: N) has reached a settlement with Mylan Pharmaceuticals, part of Viatris (Nasdaq: VTRS), concluding a US ...

Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.

Biocon, Dr Reddy’s and Mankind Pharma stress on development and manufacturing of biological drugs, look to cash in on a ...

In the current market environment, investors might be more interested in generating income rather than capital gains. Today, ...

Gilead Sciences collaborates with Indian companies to produce affordable generic versions of its HIV prevention therapy, ...

Ireland based pharmaceutical company Gilead Sciences has said it will grant licences to six generic manufacturers to produce low cost lenacapavir, which has shown unprecedented efficacy at preventing ...

Pharmaceutical companies profited by raising prices: Mylan Pharmaceuticals’s EpiPen now costs $600 in the U.S., compared to $30 in some other countries. In a second clinical trial, published in the ...

The appointed independent directors are Dalip Sehgal, former Executive Director at Hindustan Lever Limited and former MD & ...

The global dysmenorrhea treatment market, valued at approximately USD 5,937.8 million in 2022, is projected to reach USD 6,324.5 million in 2023 and USD 13,106.5 million by 2032, exhibiting a CAGR of ...